Xencor (XNCR) Cash & Equivalents (2013 - 2026)
Xencor's (XNCR) quarterly Cash & Equivalents came in at $14.2 million in Q1 2026, down 64.28% year-on-year from $39.7 million in Q1 2025, and down 73.79% on a QoQ basis from $54.1 million in Q4 2025.
Xencor (XNCR) Cash & Equivalents (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash & Equivalents data on file, last reported at $14.2 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 64.28% year-over-year to $14.2 million in Q1 2026; TTM through Mar 2026 was $14.2 million, a 64.28% decrease from a year earlier, with the FY2025 full-year figure at $54.1 million, up 32.29% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $14.2 million, down from $54.1 million in the prior quarter.
- Over the last five years, Cash & Equivalents for XNCR reached as high as $78.3 million in Q1 2022 and fell as low as $14.2 million in Q1 2026.
- Historically, Cash & Equivalents has averaged $44.7 million across 5 years, with a median of $44.4 million in 2025.
- Across the five-year window, Cash & Equivalents soared 44.44% in 2025 and slumped 64.28% in 2026, its largest moves.
- Year by year, Cash & Equivalents stood at $53.9 million in 2022, then slipped by 0.28% to $53.8 million in 2023, then retreated by 24.01% to $40.9 million in 2024, then soared by 32.29% to $54.1 million in 2025, then slumped by 73.79% to $14.2 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $14.2 million in Q1 2026, $54.1 million in Q4 2025, and $28.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 440.94 Mn |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - | 14.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.17 Mn |
| Dec 31, 2025 | 54.07 Mn |
| Sep 30, 2025 | 28.29 Mn |
| Jun 30, 2025 | 44.44 Mn |
| Mar 31, 2025 | 39.68 Mn |
| Dec 31, 2024 | 40.88 Mn |
| Sep 30, 2024 | 29.03 Mn |
| Jun 30, 2024 | 30.77 Mn |
| Mar 31, 2024 | 31.03 Mn |
| Dec 31, 2023 | 53.79 Mn |
| Sep 30, 2023 | 52.73 Mn |
| Jun 30, 2023 | 34.71 Mn |
| Mar 31, 2023 | 72.39 Mn |
| Dec 31, 2022 | 53.94 Mn |
| Sep 30, 2022 | 52.65 Mn |
| Jun 30, 2022 | 49.41 Mn |
| Mar 31, 2022 | 78.27 Mn |
| Dec 31, 2021 | 143.48 Mn |
| Sep 30, 2021 | 41.20 Mn |
| Jun 30, 2021 | 115.84 Mn |